Business Wire

Biotest Adopts Veeva Vault eTMF for Real-Time Visibility into Study Documents and Processes

Share

Veeva Systems (NYSE: VEEV) today announced that Biotest, a German biopharmaceutical company specializing in plasma proteins, implemented Veeva Vault eTMF to achieve greater visibility across its European trials. Vault eTMF enables Biotest to manage all study documents and activities in real-time as the TMF is generated. Now the company can maintain a constant state of inspection readiness and give teams a complete view into TMF status for faster study execution.

“We are increasing our efficiency and inspection readiness due to improved accessibility of trial documents with Veeva Vault eTMF,” said Daniela Zipp, head of operations, clinical systems, and data management at Biotest. “The local Veeva team in Germany provided tremendous support to get us up and running quickly. We now have the foundation and metrics in place to improve our study processes and oversight.”

Vault eTMF enables active TMF management so Biotest can manage study processes and documents in one system, in real-time, as they are executed. Advanced reporting and dashboards provide insights into document and process status at all times. Full visibility into TMF completeness allows sponsors, CROs, and sites to work better together during trials and accelerate execution.

“Companies are modernizing clinical operations to drive more efficient trials and speed drug development,” said Rik Van Mol, vice president of Veeva Development Cloud in Europe. “Veeva Vault eTMF gives Biotest greater transparency into TMF quality to improve compliance and collaboration throughout the course of their study execution.”

Veeva Vault eTMF is part of the Veeva Vault Clinical Suite, the industry’s first cloud platform that includes CDMS, CTMS, eTMF, and study start-up to unify clinical data management and clinical operations. Veeva’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes. For more information, visit veeva.com/Clinical.

Additional Information

For more on Veeva Vault eTMF, visit: veeva.com/eTMF
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors, and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Learn more at www.biotest.com.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datasite Enters Agreement to be Acquired by CapVest19.10.2020 22:00:00 EESTPress release

Datasite® (the “Company”), has entered into an agreement to be acquired by funds managed by CapVest Partners LLP (“CapVest”), an international private equity firm. Headquartered in Minneapolis, Datasite is a leading SaaS provider for the mergers & acquisitions (M&A) industry, with more than 750 employees in 25 locations across 13 countries. Over the last five years, Datasite has built a rapidly growing customer base in over 180 countries and its award-winning products and services make it a truly global player in this market. In 2019, Datasite increased revenue by more than 30% as it facilitated close to 10,000 deals. The transaction represents an important milestone for Datasite, which empowers dealmakers around the world with the tools they need to succeed across the entire deal lifecycle, including its core due diligence application, Datasite Diligence™, its application to aid the preparation of transactions, Datasite Prepare™, its application for optimizing the early stage marketin

Successful Certification of Kalray’s Smart Storage Adapter19.10.2020 19:00:00 EESTPress release

Kalray (Paris:ALKAL) (Euronext Growth Paris: FR0010722819 – ALKAL), a pioneer in processors for new intelligent systems, today announced that its K200™ Coolidge™ based smart storage adapter solution has been certified for NVM ExpressTM over Fabrics (NVMe-oF) with TCP (NVMe™/TCP) protocol by the NVM Express organization through the University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent testing provider of standard conformance solutions and multi-vendor interoperability. Data Centers are undergoing a very important revolution with rapidly evolving network architectures and technologies. This is mainly due to the explosion of usages, the surge of data to be processed and the resulting exponential growth of the number of machines to be managed to support this growth. Until now, storage has been one major bottleneck of this expansion. The introduction of flash memory-based SDD (Solid-State Drive) with hyper-fast communication protocols such as NVMe™/TCP, offers a

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients19.10.2020 18:29:00 EESTPress release

Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs). FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A. The development of inhibitors against exogenous FVIII can reduce the effectiveness of treatment and negatively impact a patient's long-term joint health and quality of life. Minimising the risk of inhibitor development is therefore a key consideration in treatment decisions for PUPs. The updated NUWIQ® PI includes data from the NuProtect study, which was the largest prospective study of a single FVIII product in true PUPs. Patients rec

Activist Malala Yousafzai and American Football Coach Katie Sowers Among Others to Headline PMI® Virtual Experience Series19.10.2020 16:00:00 EESTPress release

Project Management Institute (PMI), the world's leading association for the project management profession, is providing professionals around the world the opportunity to join three more groundbreaking Virtual Experience Series events on 20 October 2020, 12 November 2020, and 9 December 2020. Hosted by journalist, television host, and executive producer Tamron Hall, these online events connect attendees to hear unique perspectives and lessons-learned from inspiring thought leaders and experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005488/en/ Hear Pakistani education activist and the youngest Nobel Prize laureate, Malala Yousafzai, speak about advancing female education and enabling women’s leadership globally. (Photo: Business Wire) “By bringing these topics to light and providing them a global stage, we can embolden people to embrace change and lean in to new opportunities,” said Sunil Prashara, president and

Bentley Systems announces Executive Appointments of Nicholas Cumins (Chief Product Officer), Katriona Lord-Levins (Chief Success Officer), and Chris Bradshaw (Chief Marketing Officer)19.10.2020 16:00:00 EESTPress release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, announced today, following the initial public offering of its stock on September 23, the company’s successful recruitment for three significant operating positions. All three new executives are presently in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005179/en/ Nicholas Cumins, Chief Product Officer, Bentley Systems (Photo: Business Wire) Greg Bentley said, “While Bentley Systems accomplished much throughout our 36 years of growth as a privately-held company, and I am proud of our executive talent depth, we obviously could not internally develop public company experience. The principal purpose of our IPO last month was to assure market liquidity for our colleagues, and especially executive shareholders, in advance of many anticipated retirements. In turn, for the executive opportunities accordingly created, our new h

FutureOn Secures Investment from the Bentley Acceleration Fund for Oil & Gas Digitalization19.10.2020 16:00:00 EESTPress release

FutureOn, the fast-growing Norwegian software company that works with an expanding portfolio of global energy companies, announced today that it has secured an investment from the Bentley Acceleration Fund and established a strategic partnership with US-based Bentley Systems to accelerate the digitalization of the oil and gas industry. FutureOn and Bentley Systems (Nasdaq: BSY), the infrastructure engineering software company, will combine FutureOn’s award-winning field design application (FieldAP) and its API-centric collaboration platform (FieldTwin) with Bentley’s iTwin platform to provide customers a next-generation digital twin solution capable of driving design methodologies in upstream project development for the next decade. Both FutureOn and Bentley platforms use open web standards to facilitate complex integration and customization, and the combined offerings are already being implemented in exploration and production workflows. “This is a significant milestone for FutureOn w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom